Mifepristoneisaprogesteronereceptor(PR)antagonist(IC₅₀=0.2nM)inaT47Dcell-basedassay,alsoisaglucocorticoidreceptor(GR)antagonist(IC₅₀=2.6nM)inanA549cell-basedassay.

IC50:0.2nM(progesteronereceptor,inT47Dcells),2.6nM(glucocorticoidreceptor,inA549cells)^[1]

Thediscoveryofthefirstcompetitiveprogesteroneantagonist,Mifepristone,hasstimulatedanintensesearchformorepotentandmoreselectiveantiprogestins^[1].Cellgrowthisevaluatedafter4daysofexposuretoMifepristoneat10μM,aconcentrationclosetotheplasmaconcentrationachievableinhumans.TheantiproliferativeeffectofCisplatinispotentiatedwhenadministeredincombinationwithMifepristoneinHeLacells.TheIC₅₀ofCisplatinincombinationwithMifepristoneislower(14.2μM)thanthatofCisplatinalone(34.2μM)inHeLacellswithanapproximately2.5-folddifference.AftertreatmentwithMifepristone,theaccumulationofintracellularCisplatininHeLacellsis2-foldgreater,representingasignificantdifference(p=0.009),comparewithCisplatinalonefrom0.79to1.52μg/mgofprotein^[2].

ThecervixtumorxenograftmodelsaretreatedwithCisplatinalone,thereisatumorgrowthinhibitioncomparewithcontrolgroup.However,thetumorweightlossisevenmoresignificant(p<0.05) with="" the="" combination="" of="" cisplatin="" and="" mifepristone="" at="" the="" doses="" used,="" showing="" a="" decrease="" of="" ~50%="" compared="" with="" the="" treatments="" alone="" by="" the="" end="" of="" the="">^[2].AdultmaleSprague-Dawleyratsaresubjectedtoa4-daybinge-likeEtOHadministrationregimen(3to5g/kg/i.g.every8hoursdesignedtoproducepeakbloodEtOHlevels(BELs)of<300 mg/dl).="" subgroups="" of="" animals="" receive="" s.c.="" injection="" of="" mifepristone="" (20="" or="" 40="" mg/kg="" in="" peanut="" oil).="" although="" mifepristone="" produces="" no="" significant="" changes="" in="" behavior="" of="" etoh-naïve="" animals,="" pretreatment="" with="" mifepristone="" (40="" mg/kg)="" significantly="" reducesthe="" severity="" of="" etoh="" withdrawal.="" asignificant="" interaction="" between="" diet="" and="" drug,="" f(5,55)="3.92,"><0.05, such="" that="" etoh-treated="" animals="" receiving="" vehicle="" or="" 20="" mg/kg="" of="" mifepristone="" displayssignificantly="" more="" signs="" of="" etoh="" withdrawal="" than="" does="" etoh-naïve="" animals="" receiving="" the="" same="" drug="" treatment.="" importantly,="" treatment="" with="" 40="" mg/kg="" of="" mifepristone="" significantly="" reduces="" the="" severity="" of="" etoh="" withdrawal,="" in="" a="" dose-dependent="">^[3].

• [1].JiangW,etal.Newprogesteronereceptorantagonists:phosphorus-containing11beta-aryl-substitutedsteroids.BioorgMedChem.2006Oct1;14(19):6726-32.

  [2].JuradoR,etal.Cisplatincytotoxicityisincreasedbymifepristoneincervicalcarcinoma:aninvitroandinvivostudy.OncolRep.2009Nov;22(5):1237-45.

  [3].Sharrett-FieldL,etal.MifepristonePretreatmentReducesEthanolWithdrawalSeverityInVivo.AlcoholClinExpRes.2013Aug;37(8):1417-23.

T47Dhumanbreastcancercellsareplatedin96-welltissuecultureplatesat10,000cellsperwellinassaymedium[RPMImediumwithoutphenolredcontaining5%(v/v)charcoal-treatedFBSand1%(v/v)penicillin-streptomycin].Twodayslater,themediumisdecantedandMifepristoneorcontrolisaddedatafinalconcentrationof0.1%(v/v)dimethylsulfoxideinfreshassaymedium.Twenty-fourhourslater,analkalinephosphataseassayisperformedusingaSEAPkit.Briefly,themediumisdecantedandthecellsarefixedfor30minatroomtemperaturewith5%(v/v)formalin.ThecellsarewashedonceatroomtemperaturewithHanks’bufferedsalinesolution.Equalvolumes(0.05mL)of1×dilutionbuffer,assaybuffer,and1:20substrate/enhancermixturearethenadded.Aftera1-hincubationatroomtemperatureinthedark,thelysateistransferredtoawhite96-wellplateandluminescenceisreadusingaLuminoSkanAscent^[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

Mifepristoneisreconstitutedinabsoluteethanolandstored(-20˚C),andthendilutedwithappropriatemediabeforeuse^[2].

TheHeLaandCaSkihumancervicalcancercelllinesareused.TheeffectofMifepristoneonproliferationofcellsexposedtoCisplatinisevaluatedusingtheXTTassay.TheassayisbasedonthecleavageoftheyellowtetrazoliumsaltXTTtoformanorangeformazandyebymetabolicallyactivecells.Theprocedureisasfollows.Cellsareseededinto96-wellplates;Costaratadensityof6×10³viablecellsperwellin100μLculturemedium.AttheendoftreatmentwithCisplatinaloneorthecombinationofCisplatinplusMifepristone,50μLXTTisaddedtoeachwell(finalconcentration0.3mg/mL),followbyincubationfor4hinahumidifiedatmospherecontaining5%CO₂at37˚C.Theabsorbanceofthesamplesismeasuredspectrophotometricallyat492nmusingamicrotiterplateELISAreader^[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

MifepristoneissUSPendedinpeanutoil(Rat)^[3].

Mice^[2]
FemaleNudemicebetween6-8weeksofageareimplantedsubcutaneouslywith6×10⁶HeLacellsinaflank.Oncetumorsare~5×5mm,theanimalsarepair-matchedintotreatmentandcontrolgroups.Eachgroupconsistof8tumor-bearingmice.Theintraperitonealadministrationofdrugsorvehiclebeginonday0.Cisplatin,asasingleagent,isadministeredintraperitoneallyatadoseof3mg/kgdailyondays1through3;thedoseofMifepristone,asasingleagent,is2mg/kg/daysubcutaneouslyfor3days;inthecombinationstudy,themiceconcurrentlyreceiveCisplatinonthesameschedule,andMifepristoneatthesamedose3daysprevioustotheadministrationofCisplatin.Thecontrolanimalsreceiveonlythevehicle.Afteradministrationofthedrugs,miceareweighedandthetumorsaremeasuredwithacalipertwiceweekly.Thetumorweightiscalculated.Experimentisconductedfor74days,afterwhichtimeallanimalsareweighedandhumanelyeuthanized.
Rat^[3]
AdultmaleSprague-Dawleyrats,weighingbetween224and245guponarrival,areused.Mifepristone(20or40mg/kg)orvehicle(peanutoil)areadministeredsubcutaneously(s.c.)oncedailyfollowingthe0800administrationofEtOHorcontroldiet.Mifepristoneissuspendedinpeanutoilandsonicatedfor30minutesatleast24hourspriortoinjection,itisthenstoredat4°Cuntilneeded.Suspensionisvortexedfor10to15minutespriortoandasneededthroughoutdosing.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

• [1].JiangW,etal.Newprogesteronereceptorantagonists:phosphorus-containing11beta-aryl-substitutedsteroids.BioorgMedChem.2006Oct1;14(19):6726-32.

  [2].JuradoR,etal.Cisplatincytotoxicityisincreasedbymifepristoneincervicalcarcinoma:aninvitroandinvivostudy.OncolRep.2009Nov;22(5):1237-45.

  [3].Sharrett-FieldL,etal.MifepristonePretreatmentReducesEthanolWithdrawalSeverityInVivo.AlcoholClinExpRes.2013Aug;37(8):1417-23.

429.59

C₂₉H₃₅NO₂

84371-65-3

RoomtemperatureincontinentalUS;mayvaryelsewhere

DMSO:≥59mg/mL

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:98.17%

SelectBatch:HY-13683-12913

DataSheet(127KB)SDS(389KB)

COA(95KB)HNMR(345KB)LCMS(145KB)

HandlingInstructions(1252KB)

• [1].JiangW,etal.Newprogesteronereceptorantagonists:phosphorus-containing11beta-aryl-substitutedsteroids.BioorgMedChem.2006Oct1;14(19):6726-32.

  [2].JuradoR,etal.Cisplatincytotoxicityisincreasedbymifepristoneincervicalcarcinoma:aninvitroandinvivostudy.OncolRep.2009Nov;22(5):1237-45.

  [3].Sharrett-FieldL,etal.MifepristonePretreatmentReducesEthanolWithdrawalSeverityInVivo.AlcoholClinExpRes.2013Aug;37(8):1417-23.

品牌介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH，5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50～89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者，应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射，并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似，均可达81%～100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用，可加快代谢，故快代谢型者需增加剂量，慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶，熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride)：C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应，可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品

公司介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-

品牌分类

黄酮类化合物 抑制性抗体 苯丙素类 酸和醛 醌类 肽 其他 酚类 萜类和糖苷类

类固醇 生物碱 糖类和糖苷类 染料试剂 生化分析试剂

显示分类

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.medchemexpress.com/

快速导航：

公司介绍

产品中心

新闻动态

在线咨询

联系我们

公司介绍

产品中心

新闻动态

在线咨询

联系我们

总部地址：

江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)

工作时间：周一至周五9:00~18:00

技术支持：

Email：info@ebiomall.com

短信：18915418616

服务热线：

4000-520-616（全国）

☏  0512-67156496（苏州）

版权信息：

©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国

网站备案：

苏ICP备17049038号-1

苏公网安备 32059002001627号

友情链接：

联系QQ:764052152

medix采购 medkoo正品 megazyme代购 microspheres官网 midlandsci报价 minerva清关 molecular molinnov moltox mpbio RevMAb中国 ​​polysciences药物筛选 enogene公司 Viskase Corporation Apohtech产品代理 美国Novus Immunology Consultan 蚂蚁淘 广东海达仪器制造有限公司

免责声明：

本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。

扫描二维码关注官方微信

获取最新促销及产品信息